UK Markets close in 4 hrs 26 mins
  • FTSE 100

    6,674.02
    +15.05 (+0.23%)
     
  • FTSE 250

    21,269.47
    -43.18 (-0.20%)
     
  • AIM

    1,194.66
    +6.40 (+0.54%)
     
  • GBP/EUR

    1.1558
    -0.0065 (-0.56%)
     
  • GBP/USD

    1.4139
    -0.0002 (-0.0156%)
     
  • BTC-GBP

    35,650.70
    -33.20 (-0.09%)
     
  • CMC Crypto 200

    1,008.67
    +14.01 (+1.41%)
     
  • S&P 500

    3,925.43
    +44.06 (+1.14%)
     
  • DOW

    31,961.86
    +424.51 (+1.35%)
     
  • CRUDE OIL

    63.40
    +0.18 (+0.28%)
     
  • GOLD FUTURES

    1,782.80
    -15.10 (-0.84%)
     
  • NIKKEI 225

    30,168.27
    +496.57 (+1.67%)
     
  • HANG SENG

    30,074.17
    +355.93 (+1.20%)
     
  • DAX

    13,909.66
    -66.34 (-0.47%)
     
  • CAC 40

    5,797.74
    -0.24 (-0.00%)
     

Successful start to FY 2020/21 for Carl Zeiss Meditec

·5-min read

DGAP-News: Carl Zeiss Meditec AG / Key word(s): Quarterly / Interim Statement/Quarter Results
08.02.2021 / 07:00
The issuer is solely responsible for the content of this announcement.

Successful start to FY 2020/21 for Carl Zeiss Meditec
 

Revenue in first three months back to prior-year level; increase in operating profit due to lower costs

 

JENA, 8 February 2021

Carl Zeiss Meditec generated revenue of €368.9m in the first three months of fiscal year 2020/21 (prior year: €369.7m), corresponding to a decline of just -0.2% (adjusted for currency effects: +2.6%) compared with the year-ago period, which had not yet been impacted by the COVID-19 pandemic. Earnings before interest and tax (EBIT) increased to €73.4m (prior year: €56.8m). The EBIT margin was 19.9% (prior year: 15.4%).

Dr. Ludwin Monz, President and CEO of Carl Zeiss Meditec AG: "This is a good start to the new fiscal year, particularly in light of the pandemic, which is still ongoing in many markets. Our diversified portfolio has once again proven to be robust. I am particularly pleased with the strong contributions to growth from the Asia/Pacific region and the good cost discipline within the Company, which played a major role in the development of earnings."

SBU Ophthalmic Devices records sales growth again for the first time since the beginning of the pandemic

Revenue in the Ophthalmic Devices strategic business unit (SBU) increased by 5.2% in the first three months of fiscal year 2020/21 (adjusted for currency effects: +8.2%) to €283.4m (prior year: €269.4m). Recurring revenue from consumables, implants and services made significant contributions to growth. Revenue in the SBU Microsurgery fell by -14.7% (adjusted for currency effects: -12.3%), to €85.5m (prior year: €100.3m). On a currency-adjusted basis, orders received in the SBU Microsurgery were already back to the prior year's level.

APAC[1] region returns to growth - EMEA[2] and Americas almost stable

Revenue in in the EMEA region decreased slightly by -1.8% (adjusted for currency effects: +0.1%), to €108.7m (prior year: €110.7m). The trend in the markets of Germany, France and Southern Europe was stable.

The Americas region recorded a mainly currency-related decline in revenue of -6.4% (adjusted for currency effects: -0.2%) to €102.0m (prior year: €109.0m). On a currency-adjusted basis, the USA almost matched the prior year's level.

Revenue in the APAC region increased again for the first time since the start of the crisis, amounting to €158.2m compared with €150.0m in the same period of the prior year (+5.5%; adjusted for currency effects: +6.6%). Once again, the strongest contributions to growth were generated in China and South Korea. There was only a slight decline in revenue in Japan.

Operating result increased significantly year-on-year

The operating result (earnings before interest and taxes: EBIT) increased to €73.4m in the first three months of fiscal year 2020/21 (prior year: €56.8m). Low selling and marketing expenses, in particular, contributed to this. EBIT also includes positive one-time income of €2.4m from the sale of a property. The EBIT margin increased to 19.9% (prior year: 15.4%). Adjusted for special effects, this resulted in an increase to 19.8% (prior year: 15.8%). Earnings per share rose to €0.52 (prior year: €0.43).

Carl Zeiss Meditec expects revenue and EBIT to continue to recover over the further course of fiscal year 2020/21 compared with the prior year, which had been dominated by the COVID-19 pandemic.

Revenue by strategic business unit

All figures in €m

3 months 2020/21

3 months 2019/20

Change from prior year

Change from prior year (currency-adjusted)

Ophthalmic Devices

283.4

269.4

+5.2%

+8.2%

Microsurgery

85.5

100.3

-14.7%

-12.3%

Consolidated

368.9

369.7

-0.2%

+2.6%

 

Revenue by region

All figures in €m

3 months 2020/21

3 months 2019/20

Change from prior year

Change from prior year (currency-adjusted)

EMEA

108.7

110.7

-1.8%

+0.1%

Americas

102.0

109.0

-6.4%

-0.2%

APAC

158.2

150.0

+5.5%

+6.6%

Consolidated

368.9

369.7

-0.2%

+2.6%

 

Further information on our publication and the Analyst Conference Call on the results for the first three months of fiscal year 2020/21 can be found at https://www.zeiss.com/meditec-ag/investor-relations/reports-publications.html

 

Contact for investors and press

Sebastian Frericks
Director Investor Relations, Carl Zeiss Meditec AG
Phone: +49 (0)3641 220-116
Email: investors.meditec@zeiss.com

www.zeiss.de/presse

[1] Asia/Pacific
[2] Europe, Middle East, Africa


08.02.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

Language:

English

Company:

Carl Zeiss Meditec AG

Göschwitzer Str. 51-52

07745 Jena, Germany

Germany

Phone:

+49 (0)3641 220-0

Fax:

+49 (0)3641 220-112

E-mail:

investors.meditec@zeiss.com

Internet:

www.zeiss.de/meditec-ag/ir

ISIN:

DE0005313704

WKN:

531370

Indices:

MDAX, TecDAX

Listed:

Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange

EQS News ID:

1166466


 

End of News

DGAP News Service

show this
show this